Home
overview

SMi are proud to present their 14th Annual Pain Therapeutics Conference taking place in Central London on Monday 19th and Tuesday 20th May 2014. 

This event will focus on the advances and challenges of pre-clinical and clinical aspects of pain drug development.

The agenda will give delegates an in-depth analysis on the strategies from bench to bedside  to enhance drug development.

New mechanisms will also play an important role when evaluating novel targets with alternative approaches to animal ‘pain’ models and personalised medicines as an exploratory area.

The translation gap between animal data and humans is significant, enabling delegates to review proof of concept for pain modelling in humans.

 New sessions for 2014 will include:


• Advances in recent neuropathic pain developments will be studied, in addition to assessing new therapeutic strategies for pain reduction

 

•Discuss and evaluate the latest new therapeutic mechanisms from bench to bedside with key insight from Merck, Spinifiex, Eli Lilly, AbbVie and UCB
•Hear key presentations from Mundipharma, Nektar and on advances to opioids and strategies to reduce abuse potential
•Explore the latest in the area of Neuropathic pain for 2014 with the latest case studies from Neuroscience Technologies and GW Pharmaceuticals
•Evaluate the translation gap with case studies from a pre-clinical and clinical perspective from Karolinska Institutet and OGB Consulting
 

 Chief Executive Officer, Chief Scientific Officers, Managing Directors, Head of Department, Team Leaders, Principal Research Scientists in the following fields:

• Pain and Migraine
• Inflammation
• Chronic Pain
• Neuropathic Pain
• Analgesic pre-clinical development
• Anaesthesia and Pain Management
• CNS clinical trials
• Ion Channel Pharmacology
• Pharmacology Intelligence

 

Aalborg University; ACRAF S.P.A.; Amgen; Aptuit; Arachos Pharma; Astellas pharma Kft; Biotrial International; Boehringer-Ingelheim Pharma; Bristol-Myers Squibb Pharmaceuticals Ltd; Cambridge University; Cellectricon; Cellectricon AB; Convergence Pharmaceuticals; Daiichi-Sankyo; Eisai Europe Ltd; Eurofins Pan Labs; Grunenthal Gmb H; Icon Development Solutions Ltd; Indena S P A; Independent Consultant; Johnson & Johnson; Johnson & Johnson Pharmaceutical; Leoben Research Limited; MD Biosciences; MedImmune; Mundipharma Research ; Mundipharma Research GmbH & Co. KG; Nektar Therapeutics; Orion Pharma; Orion Pharma UK; Pacira Pharmaceuticals Inc; Paediatric Research Consultancy; Pfizer; Pfizer Global Research & Development; Queen Mary College, Univeristy of London; Stanford University School Of Medicine; Takeda Cambridge Ltd; Teva Pharmaceuticals; Teva Pharmaceuticals Ltd.; THE ANN HAYES CONSULTANCY; The Lewisham Hospital N H S Trust; The University Of Sheffield; University of Cambridge; University Of Groningen; University of Manchester; University of Nottingham; Vertex Pharmaceuticlas (Europe) Ltd; VETOQUINOL;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Kathleen Kelly

Kathleen Kelly, Medical Leader, Janssen Pharmaceutical Research and Development LLC

9:10 Overview of Fulranumab Clinical Development

Kathleen Kelly

Kathleen Kelly, Medical Leader, Janssen Pharmaceutical Research and Development LLC

  • Nerve Growth factor (NGF) is elevated in tissues in response to injury and inflammation
  •  Antibody inhibitors of NGF have shown efficacy in treating pain
  • Fulranumab is a fully human monoclonal antibody inhibitor of NGF in development
  • Phase 2 efficacy and safety data for fulranumab will be presented
  • 9:50 Strategies for Designing Novel Therapeutic Modulators

    Zara Sands

    Zara Sands, Computational Medicinial Chemist, UCB

  • Importance of establishing expectations and aligning resources accordingly
  • Examples of effective applications of computational approaches for driving drug design cycles
  • Potenital pit falls and future prospects
  • 10:30 Morning Coffee

    11:00 Mechanistic studies supporting the angiotensin II type 2 receptor antagonist MOA in chronic pain through to presentation of Phase 2 efficacy and safety data

    Tom McCarthy

    Tom McCarthy, Chief Executive Officer and Managing Director, Spinifex Pharmaceuticals

  • Efficacy data from a 183 patient Phase 2 clinical trial of EMA401 in patients with post herpetic neuralgia
  • Safety data from the above study
  • Update on ongoing clinical trials of EMA401
  • 12:20 Round Table Discussion: Should animal models only be used for PK/PD testing for exposure of the compound?

    12:50 Networking Lunch

    13:50 How do we produce a step change in the discovery of new analgesics?

    Chas Bountra

    Chas Bountra, Chief Scientist, Structural Genomics Consortium, University of Oxford

  • Epigenetic proteins are fundamental mediators of chronic pain pathology
  • In early discovery, more open partnerships between academia and industry are critical
  • In vitro clinical assays are likely more perspective of activity in patients
  • 14:30 Highlights from AbbVie Pain Research: TRPV1, TrkA, Cav2.2, and Nav1.7

    Philip Kym

    Philip Kym, Associate Director II, Pain Discovery Research, Abbott Laboratories

  • The discovery of modality specific TRPV1 antagonists that demonstrate reduced liabilities with respect to core body temperature increase and the loss of sensation of noxious heat.
  •  The discovery of Cav2.2 and Nav1.7 clinical candidates for the treatment of chronic pain.
  • The discovery of TrkA inhibitors for the treatment of chronic pain.
  •  

    15:10 Afternoon Tea

    15:40 The Translational Gap and Assessing Failures Case Study 1: Pre-Clinical Perspective

    Odd-Geir  Berge

    Odd-Geir Berge, Independent Consultant, OGBConsulting

  • Experimental models versus clinical trials
  • Translation from animal models to man
  • Failed pain mechanisms? 
  • 16:20 The Translational Gap and Assessing Failures Case Study 2:Clinical Perspective

    Jarkko Kalliomaki

    Jarkko Kalliomaki , Senior Consultant Physician , Stockholm Brain Institute

  • Translation from a clinical perspective
  • Human proof of concept
  • Failed mechanisms or failed studies? 
  • 17:00 Panel Discussion

  • Addressing issues in clinical trial design
  • Bridging the translational gap between animal and human model
  • Identifying key challenges in design when bench marking
  • Odd-Geir  Berge

    Odd-Geir Berge, Independent Consultant, OGBConsulting

    Steve  Harrison

    Steve Harrison, Vice President, Research Biology, Nektar Therapeutics

    Jarkko Kalliomaki

    Jarkko Kalliomaki , Senior Consultant Physician , Stockholm Brain Institute

    Birgit  Priest

    Birgit Priest , Senior Scientist , Eli Lilly

    17:40 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Jordi Serra

    Jordi Serra, CSO , Neuroscience Technologies Ltd

    9:10 Opioids and the Treatmnet of Chronic Pain

    Alexander Oksche

    Alexander Oksche, Exec Director European Pharmacol Intelligence, Mundipharma Research GmbH & Co. KG

  • How has the new form of Oxycontin made a difference- controlled release
  • Reviewing novel formulation strategies to reduce opioid abuse
  • Analysing the recent advances to opioids – moving forward
  • 9:50 Novel Opioid Therapuetics with Intrinsically Reduced Abuse Potential

    Steve  Harrison

    Steve Harrison, Vice President, Research Biology, Nektar Therapeutics

  • NKTR-181, a slow brain entry opioid for Chronic Pain
  • Opioid therapeutics with novel pharmacoloyg for the treatment of actue pain
  • 10:30 Morning Coffee

    11:00 Zero Tolerance for Chronic Pain

    Howard Gutstein

    Howard Gutstein, Professor, Department of Anesthesiology and Biochemistry, Anderson Cancer Center

  • Growth factor signaling selectively mediates tolerance to morphine.
  • Growth factor inhibition eliminates or reverses morphine tolerance.
  • Newly discovered relationships between opioid tolerance and neuropathic pain suggests that this class of drugs could become important therapeutic targets for pain treatment
  • 11:40 Discussion Panel: Strategies for reduced abuse potential

  • Insights into the future of opioids
  • Assessing alternatives to opioid therapeutics
  • Evaluating how to move forward to minimise opioid misuse
  • Alexander Oksche

    Alexander Oksche, Exec Director European Pharmacol Intelligence, Mundipharma Research GmbH & Co. KG

    Steve  Harrison

    Steve Harrison, Vice President, Research Biology, Nektar Therapeutics

    Howard Gutstein

    Howard Gutstein, Professor, Department of Anesthesiology and Biochemistry, Anderson Cancer Center

    12:20 Networking Lunch

    13:20 Translational Pain Medicine (TPM) - assessing pain mechanisms

    Misha  Backonja

    Misha Backonja, Medical Director, Neuroscience , PRA International

  • Current status of translational research in pain 
  • Missing link - bedside to bench and its relevance
  • Standards in utilizing the best tool - QST
  • Interpretation of results in TPM
  • 14:00 New Tools in the Translation from Bench to Clinic

    Birgit  Priest

    Birgit Priest , Senior Scientist , Eli Lilly

  • Failure of recent developmental compounds to demonstrate analgesic efficacy in the clinic
  • Possible explanations based on divergent pharmacology
  • New tools and approahces to better predict human pharmacology and efficacy
  • 14:40 Microneurography as a method for recording individual action potentials from nociceptors and its value in drug development in neuropathic pain.

    Jordi Serra

    Jordi Serra, CSO , Neuroscience Technologies Ltd

  • Analysing analgesic efficacy in preclinical animal modells
  • Reviewing proof-of-concept studies that allow critical testing of presumed mechanism of actions
  • Recording individual action potentials from single sensory fibers, including nociceptors to detect and quantify abnormal activity in human pain fibers
  • 15:20 Afternoon Tea

    15:50 Cannabinoids in neuropathic pain: what have we learnt?

    Stephen Wright

    Stephen Wright, Director, R&D, G W Pharmaceuticals

  • Responses to cannabinoids across different neuropathic pain types
  • The importance of non-psychoactive cannabinoids
  • Cannabinoid modulation of neurotransmission vs inflammation
  • 16:30 Advances into new therapeutic strategies for chronic pain

    Fiona Boissonade

    Fiona Boissonade, Head of Neuroscience Research Group, The University Of Sheffield

  • Correlation between degree of pain and molecular targets in man
  • Translation from preclinical models
  • Interventions to prevent or reverse neuropathic pain
  • 17:10 Chairman's Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Birgit  Priest

    Birgit Priest

    Senior Scientist , Eli Lilly
    Kathleen Kelly

    Kathleen Kelly

    Medical Leader, Janssen Pharmaceutical Research and Development LLC
    Misha  Backonja

    Misha Backonja

    Medical Director, Neuroscience , PRA International
    Tom McCarthy

    Tom McCarthy

    Chief Executive Officer and Managing Director, Spinifex Pharmaceuticals
    Zara Sands

    Zara Sands

    Computational Medicinial Chemist, UCB

    Alexander Oksche

    Exec Director European Pharmacol Intelligence, Mundipharma Research GmbH & Co. KG
    Alexander Oksche

    Birgit Priest

    Senior Scientist , Eli Lilly
    Birgit  Priest

    Chas Bountra

    Chief Scientist, Structural Genomics Consortium, University of Oxford
    Chas Bountra

    Fiona Boissonade

    Head of Neuroscience Research Group, The University Of Sheffield
    Fiona Boissonade

    Howard Gutstein

    Professor, Department of Anesthesiology and Biochemistry, Anderson Cancer Center
    Howard Gutstein

    Jarkko Kalliomaki

    Senior Consultant Physician , Stockholm Brain Institute
    Jarkko Kalliomaki

    Jordi Serra

    CSO , Neuroscience Technologies Ltd
    Jordi Serra

    Kathleen Kelly

    Medical Leader, Janssen Pharmaceutical Research and Development LLC
    Kathleen Kelly

    Misha Backonja

    Medical Director, Neuroscience , PRA International
    Misha  Backonja

    Odd-Geir Berge

    Independent Consultant, OGBConsulting
    Odd-Geir  Berge

    Philip Kym

    Associate Director II, Pain Discovery Research, Abbott Laboratories
    Philip Kym

    Praveen Anand

    Professor, Clinical Neurology,, Imperial College London
    Praveen Anand

    Stephen Wright

    Director, R&D, G W Pharmaceuticals
    Stephen Wright

    Steve Harrison

    Vice President, Research Biology, Nektar Therapeutics
    Steve  Harrison

    Tom McCarthy

    Chief Executive Officer and Managing Director, Spinifex Pharmaceuticals
    Tom McCarthy

    Zara Sands

    Computational Medicinial Chemist, UCB
    Zara Sands

    Interview with OGBConsulting

    Download

    Interview with Philip Kym

    Download

    Holiday Inn Kensington Forum

    97 Cromwell Road
    London SW7 4DN
    United Kingdom

    Holiday Inn Kensington Forum

    Holiday Inn Kensington Forum is perfectly situated in one of London’s most luxurious and beautiful areas within South Kensington. 

    The hotel is just 2 minutes walk from Gloucester Road tube station for convenient travel to Hyde Park, London Eye, Tower Bridge plus more of London’s top attractions. There are also easy and direct links to some major transport hubs including Victoria, Kings Cross St Pancras, Paddington and Heathrow. 

    This distinctive hotel in south London has so much to offer to make all guests really feel at home. The latest Holiday Inn relaunch is not just about the new look and feel for the hotel but to offer guests more benefits during their stay including a pillow menu for extra comfort during their sleep and a curved shower rail for more spacious feel. 

    In addition to our 906 rooms, all business guests can take advantage of our meeting and conference facilities including High Speed Internet Access and unlimited Starbucks coffee at The Academy. Our hotel’s professional event planners are on board to help take the hard work and stress away from planning your next event. 

    So whether you in London on business or pleasure, make the Holiday Inn London Kensington Forum your first choice of hotel and book your accommodation for our lowest internet rate guarantee. 

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.